CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
October 2014—SeraCare Life Sciences announced the launch of its Accurun 501 C. difficile Control, the company’s first molecular control product targeting hospital-acquired infections.
Accurun 501 C. difficile Control is formulated for use with in vitro diagnostic tests that detect C. difficile DNA in human stool samples. Manufactured from cultured Clostridium bacteria of four different strains or species delivered in a set of four vials, the bacteria are inactivated and in a human synthetic stool matrix. The control is ready to use in assays that detect C. difficile DNA with any transport system.
SeraCare Life Sciences, 800-676-1881